CLINICAL TRIAL

Liposomal bupivacaine for Agnosia

Recruiting · 18+ · Female · Baltimore, MD

This study is evaluating whether a new type of pain medication may be as effective as a traditional epidural for individuals undergoing gynecological surgery.

See full description

About the trial for Agnosia

Eligible Conditions
Agnosia · Surgery · Analgesia

Treatment Groups

This trial involves 2 different treatments. Liposomal Bupivacaine is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.

Experimental Group 1
Thoracic epidural analgesia (bupivacaine)
OTHER
Experimental Group 2
Liposomal bupivacaine
DRUG

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bupivacaine
FDA approved

Eligibility

This trial is for female patients aged 18 and older. There are 2 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Individuals ≥ 18 years of age
The gynecologic oncology service at the sponsor institution plans to perform a laparotomy. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Up to 1 year
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Up to 1 year.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Liposomal bupivacaine will improve 2 primary outcomes and 26 secondary outcomes in patients with Agnosia. Measurement will happen over the course of Baseline and postoperative day 7.

Change in Anti-diuretic hormone (ADH) level
BASELINE AND POSTOPERATIVE DAY 7
ADH level in pg/mL.
Change in Glycosaminoglycans level (ng/mL)
BASELINE AND POSTOPERATIVE DAY 7
Change in Salivary cortisol (microgram/dL) level
BASELINE AND POSTOPERATIVE DAY 7
Change in C-reactive protein level (ng/mL)
BASELINE AND POSTOPERATIVE DAY 7
Change in Interleukin-6 level (pg/mL)
BASELINE AND POSTOPERATIVE DAY 7
Change in Tumor necrosis factor alpha (TNF-α) level
BASELINE AND POSTOPERATIVE DAY 7
TNF-α level in pg/mL.
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the latest research for agnosia?

Current research confirms and extends previous findings suggesting that agnosia is a multifactorial illness. It is now known to be associated with damage to the medial temporal cortical regions, and with functional abnormalities of working memory.

Anonymous Patient Answer

How many people get agnosia a year in the United States?

Findings from a recent study suggest that approximately 1 in 100 Medicare beneficiaries are affected by VA-funded screening for a variety of conditions that cause cognitive dysfunction. Additional screening of this nature is warranted, even if current medical treatments are not available.

Anonymous Patient Answer

What are the signs of agnosia?

Many people are unaware of their visual and other sensory deficiencies.\n\nPatients and their relatives may present with signs of depression, anxiety, psychosis, psychosis mood disorders and personality disturbance, which can have significant consequences for care.\n\nThere are a number of psychiatric disorders that may be secondary to dementia,\nsome as pictured are Alzheimer's disease,\nParkinson's disease,\nHuntington disease, and\nPrion disease.

Anonymous Patient Answer

What causes agnosia?

The study of the brain's anatomy and how the brain deals with the sense of touch, especially in the left-handed and right-handed is particularly notable. This research would be informative in considering the causes of agnosia and other unilateral neglects as well as other forms of spatial neglect such as spino-parietal neglect.

Anonymous Patient Answer

Can agnosia be cured?

The patient had not been exposed to stimuli similar in form and location to the stimuli she could not recognize. However, this patient did have specific deficits in visual processing (her agnosia) which have been found in patients after visual-spatial deafferentation. Therefore, her deficits may be the result of vision deprivation.

Anonymous Patient Answer

What are common treatments for agnosia?

Many patients treated for agnosia with medication and various physical and cognitive interventions require prolonged rehabilitation afterward to improve their ability to relearn everyday tasks and perform basic tasks.

Anonymous Patient Answer

What is agnosia?

The agnosic patient illustrates that we cannot assume agnosias must involve only the visual sensory system, when the auditory system is functionally intact. However, although the patient exhibits normal recognition for simple visual features the agnosic patient cannot identify speech sounds and this finding demonstrates a profound deficit in verbal lexical storage capabilities. Although one could argue that the patient's deficit exists because she is unable to learn from verbal presentation of familiar voices (namely her mother's voice), she appears to be able to perceive speech from another individual when she does not require that individual to speak.

Anonymous Patient Answer

How serious can agnosia be?

Recent findings of 11 patients with agnosia demonstrates that most forms of agnosia can result in severe disability. The consequences of agnosia can be severe enough that people are often diagnosed with the condition and consequently have to have counseling and support from their physician as they develop the condition's symptoms during their lifetime. Clinicians need to be particularly mindful of potential severe symptoms of agnosia and their consequences with the diagnosis and treatment of this condition.

Anonymous Patient Answer

What is the average age someone gets agnosia?

On average, agnosia first occurs after the onset of deafness, age 55, and is most common among people 70 and older. Since these are the cohorts most at risk for developing dementia, and a diagnosis of dementia is itself a form of agnosia, the results of the study suggest that, in many cases, the onset of dementia occurs within the window of time when sufferers of deafness are more likely to have a diagnosis of agnosia. It will be essential to develop effective and accessible early intervention strategies for people with auditory problems if we are to slow the rapid rise in the number of people with dementia due to vascular cause.

Anonymous Patient Answer

How does liposomal bupivacaine work?

Using a different formulation (Liposomal bupivacaine for pain relief after dental treatment) was found to significantly improve pain and pain relief over bupivacaine administered by infiltration, and resulted in a significant reduction in narcotic consumption without delaying or reducing recovery after treatment.

Anonymous Patient Answer

What does liposomal bupivacaine usually treat?

We have not yet found any data that support the use of liposomal bupivacaine in pediatric patients. It might be safer to administer the medication intravenously or intrapleurally, in accordance with the clinician's judgment.

Anonymous Patient Answer

Have there been other clinical trials involving liposomal bupivacaine?

According to our study, the local analgesia of bupivacaine liposomes is similar to conventional bupivacaine. The local anesthetic duration is significantly longer than the conventional bupivacaine, but the patient tolerates this local anesthesia well and in the case of bupivacaine liposomes, there were no severe side effects or cardiac events. Further studies are needed to examine the optimal time of bupivacaine application for liposome-mediated blockade.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Agnosia by sharing your contact details with the study coordinator.